Clinical Trial: A Multicenter, Randomized, Open-Label, Blinded-Endpoint Trial of Tenecteplase versus Dual Antiplatelet Therapy in Mild Disabling Ischemic Stroke with Large Vessel Occlusion Beyond 4.5 Hours (China)

China, Sept. 7 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Multicenter, Randomized, Open-Label, Blinded-Endpoint Trial of Tenecteplase versus Dual Antiplatelet Therapy in Mild Disabling Ischemic Stroke with Large Vessel Occlusion Beyond 4.5 Hours'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131721

Registration Time: 2026/09/06

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital of China Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=338346

Published by HT Digital Content Services with permission from Health Daily Digest....